Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 11th July 2019 8:15am – 9:30am
Venue	Pathology Meeting Room ,Pathology Building, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Ms J Morgan, Professional Secretary, Senior Principal Pharmacist - Formulary Dr A Samson, Infectious Diseases Consultant Dr S Raise, GP ER CCG (via phone link) Dr H Klonin, Consultant Paediatrician Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via phone link) Dr F Umerah, Consultant Anaesthetist
Apologies	Mr S P Gaines, Deputy Chief Pharmacist, Lead Pharmacist Medicine Safety Mr P O'Brien, Deputy Chief Pharmacist Prof A Morice, Chair, Professor of Respiratory Medicine Dr O Ogunbambi, Consultant Rheumatologist

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2019.07.01	**Apologies**	As above.					
2019.07.02	**Declarations of Interest**	None.					7/19
2019.07.03	**Minutes of the previous meeting**	Accepted as a true record.					7/19
2019.07.04	**Action Tracker**	**NICE Guidance** TA567 Tisagenlecleucel ML informed the committee not used at HUTH only commissioned at Newcastle	WH to add to back of formulary	WH to add to back of formulary	WH	8/19	
		NICE Guidance TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis. ML has written to dermatology	ML has written to dermatology	Action complete	ML		7/19
		NICE Guidance TA577 Brentuximab vedotin for treating CD30 positive cutaneous T-cell lymphoma. ML confirmed HUTH does not treat this condition	WH to add to back of formulary	WH to add to back of formulary	WH	8/19	
		New Product Requests AM has written to applicants and WH has updated formulary and unlicensed list	Action complete	No further action	AM		7/19
		New Product Requests SG has discussed Midazolam at SMPC. It was decided that due to the oral syringe not having an n-fit closure as per national guidance along with no dose graduations, and the fact that the oral preparation comes in glass ampoule with a filter straw, the risk for double dosing and choosing the wrong route of administration was too high, and therefore the product was rejected.	Rejected	ML to write to applicants	ML	8/19	
		New Product Requests	Rejected	ML to write to applicants	ML	8/19	

		SG has discussed Toujeo doublestar at SMPC. SMPC rejected the device as it was thought that the potential for error regarding double dosing was too high.	Action complete	No further action	AM		7/19
		MHRA DSU May 19 AM has written to clinical leads for gastroenterology and rheumatology regarding tofacitinib	Bring back next time	Leave on tracker	HK	8/19	
		MHRA DSU May 19 Magnesium Sulphate HK has discussed with Jane Allen. JM informed the committee she was awaiting response from the obstetricians as there may be some instances where two doses are given eg if a patient was undergoing a long labour.	Action complete	No further action	WH		7/19
		Correspondence Received Rivaroxaban has been added to HERPC agenda	Action complete	No further action	AM		7/19
		AOB AM has formally invited Dr Ali to attend D&T	Action complete	No further action	WH		7/19
		AOB WH has added nitrofurantoin MR 100mg to formulary					
2019.07.05	**New Product Requests**	**Melatonin Solution, Licensed Preparation Available – Line Extension** JM informed the committee that a licensed preparation of melatonin liquid was now available. The new preparation is licensed for jet lag however HUTH is not using for this indication. MHRA guidance around unlicensed medicines dictates that a licensed preparation should be used over an unlicensed preparation. JM did raise concerns regarding the amount of propylene glycol in the licensed preparation and the affect prolonged use could have on younger patients renal systems. It was asked if a liquid preparation was required and HK confirmed it was.	Deferred	Discuss further at F&W HG	JM	8/19	
		Hyfiber – Bowel Transit Disorders – Dr H Collinson The committee felt that more clinical evidence was required to consider the application	Deferred	ML to request more evidence	ML	8/19	
		Thalidomide – Nodular Prurigo – Dr A Butt Application is for use in one female patient where all other	Approved for use in 1 patient	ML to write to applicant and request IFR	ML	8/19	

		treatments have failed. Guselkumab – Severe Plaque Psoriasis TA521 – Dr Zaman	 Approved	 Pharmacy to request update to treatment flowchart	 JM	 8/19	
2019.07.06	**NICE Guidance – June 2019**	TA583 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA585 Ocrelizumab for treating primary progressive multiple sclerosis NG133 Hypertension in pregnancy: diagnosis and management Updated for removal of chlorothiazide NG134 Depression in children and young people: identification and management TA586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma NG123 Urinary incontinence and pelvic organ prolapse in women: management TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality(Update)	Endocrinology have not yet responded regarding use in line with TA572 for monotherapy Noted JM to find out if required Noted Noted Noted Noted Noted Noted	Discuss next time JM to contact Dr Harley	JM JM	8/19 8/19	

		TA171 Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies(update)	Noted				
2019.07.07	**MHRA Drug Safety Update – June 2019**	DOACs:increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome GLP-1 receptor agonists: reports of DKA when concomitant insulin was rapidly reduced Lartruvo (olartumab) withdrawal of the EU marketing authorisation due to lack of efficacy Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and woman	Noted Noted Noted JM to check educational materials. WH to add to MMIG agenda		JMWH	8/19	
2019.07.08	**Minutes from HERPC**	None this month	No further action				7/19
2019.07.09 *	**Minutes from SMPC – April 19**	DC informed the committee that SMPC are reviewing PSA's to ensure compliance and there have been concerns regarding the midazolam PSA. DC has had informal meeting with CQC where electronic prescribing and antibiotic stewardship werediscussed.	Noted	No further action			7/19
2019.07.10	**Regional Medicines Optimisation Committees**	• Newsletter number 5 • RMOC-Position-Statement-Rarely-Used-and-Urgent-Medicines • Rarely-Used-Medicines-How-to-view-them-on-Define The RUUM list has been updated, JM and LC will be checking pharmacy stock to ensure compliance.	Noted	No further action			7/19
2019.07.11	**Correspondence received**	DC informed the committee that although a licensed version of mexilitene was now available the trust are treating a cardiology patient with an unlicensed brand this was because the patient was stable on this preparation and there were concerns a switch may cause deterioration of their condition.	The committee felt that more discussion relating to use of licensed/ Unlicensed preparations was required	JM to write paper	JM	8/19	
		Avapritinib BLU-285 - Metastatic GIST – Dr G Bozas	Noted				7/19

2019.07.12	**Chairs approvals**	Tocilizumab – Chronic Idiopathic Uveitis – Dr E Baguely Gonadotrophin - hypogonadotropic hypogonadism – Dr Aye					
2019.07 13	**Issues to escalate to OQC**	No items to escalate					6/19
2019.07.14	**Any Other Business**	TA 318 Lubiprostone for treating chronic idiopathic constipation- no longer available recommend remove from formulary	WH to remove from formulary			8/19	
		Myocrisin (Sodium Aurothiomalate) Discontinuation	JM to speak to rheumatology			8/19	
		Items Which Should Not Be Routinely Prescribed	Noted				7/19
		Free Style Libre FAQs	Noted				7/19
		Signed copies of Symtuza, Maviret, Nevapine, Vosevi and Pristinamycin Applications have now been received	Noted				7/19
2019.07.15	**Date and Time of Next Meeting**	**Date:** Thursday 8th August 2019 **Time:** 8.15-9.30am **Venue:** Pathology Meeting Room					